O’Toole et al. identify novel interactors of both normal BRAF and BRAFV600E and discover TP53 as a BRAFV600E-enhanced interactor in melanoma cells. While TP53 mutations do not frequently occur in melanoma, the authors demonstrate TP53 inactivation and a sequestration of cytoplasmic TP53 after oncogenic BRAF activation.